ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
Cost of Revenue
ADC Therapeutics SA
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADC Therapeutics SA
NYSE:ADCT
|
Cost of Revenue
$-2.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
AC Immune SA
NASDAQ:ACIU
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Cost of Revenue
CHf-26.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
Idorsia Ltd
SIX:IDIA
|
Cost of Revenue
CHf-6.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
Cost of Revenue
CHf-5.1m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-121%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Cost of Revenue?
Cost of Revenue
-2.5m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Cost of Revenue amounts to -2.5m USD.
What is ADC Therapeutics SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-20%
Over the last year, the Cost of Revenue growth was -20%.